BRCA2 and neoplasm: Furthermore, mice administered the WRNi displayed elevated DNA damage and marked inhibition of BRCA2-deficient tumor growth in the xenograft model, in agreement with the hypersensitivity of BRCA2-deficient cancer cells to the WRNi.